Slide 1: Investor Update May 2022
INVESTOR UPDATE May 2022 P HI LI P DAFF AS , P AI N CHE K LTD CEO & M D ASX :P C K 1 |
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by PainChek Limited (Company) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the Corporations Act 2001 (Cth) and has not been, and
Slide 3: Corporate Overview
CORPORATE OVERVIEW • PainChek’s SAAS AI Platform uses smart devices to accurately evaluate patients’ pain levels • Improves Patient care – and saves time and money for providers • 126,000 contracted beds across 1500 facilities globally - 60% market share in Australia, UK sales accelerating, entered
Slide 4: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain 4 |
Slide 5: The Breadth of the PainChek Global Market Opportunity
THE BREADTH OF THE PAINCHEK GLOBAL MARKET OPPORTUNITY 400Mpre-verbal children 25-42% of hospital beds occupied by people with dementia 57M people living with dementia >150M expected by 2050 1. Ecology Communications Group. www.ecology.com/birth-death-rates 2. World Alzheimer Report 2016 3. Germossa
Slide 6: PainChek Adult App - Best Practice Pain Management
PAINCHEK ADULT APP - BEST PRACTICE PAIN MANAGEMENT Assess and documents for all people - accelerates adoption by new clients and supports retention of existing clients Pure SaaS Business model – annual license agreements based on bed numbers or end users Provides greater insights for medical decisio
Slide 7: Key Achievements
KEY ACHIEVEMENTS 126,000 global licenses contracted, with an expected ARR of $4.3M within First New Zealand sale rollout started with Summerset 12 months when fully implemented and transitioned - excluding new Holdings. – NZ’s 3rd largest aged care provider business . Adult and Infant Apps regulator
Slide 8: ANZ Sales and Partnership Milestones – FY22 YTD
ANZ SALES AND PARTNERSHIP MILESTONES – FY22 YTD Sumerset Group NZ Joondalup Health Finley Regional Care The Nulsen Group contracted for full Campus (Ramsay contracted as contracted as PainChek rollout Health Care) contracted PainChek’s first PainChek’s first as PainChek first commercial Home Disabil
Slide 9: UK - Rapid Entry into the 440,000 Bed Residential Aged Care Market
UK - RAPID ENTRY INTO THE 440,000 BED RESIDENTIAL AGED CARE MARKET “ The greatest achievement to date s a marked decrease in antipsychotic use in those living with dementia. UK market traction Government funded New sales with Care UK Cheryl Baird, Director of Quality growing – 5,000 pilots in Scotla
Slide 10: Strong Growth in Customer Revenue
STRONG GROWTH IN CUSTOMER REVENUE • Strong increase in Q3 FY22 Customer Revenue CUSTOMER REVENUE BY QUARTER over prior quarter (+ 66%) (MARCH 2022 UNAUDITED) - (A$) $350,000 • Growth driven by successful conversion of $300,000 +66% government funded users to commercial $250,000 subscriptions $200,00
Slide 11: Business Growth Reflected in Training & Clinical Use
BUSINESS GROWTH REFLECTED IN TRAINING & CLINICAL USE PAINCHEK® USERS NUMBER OF PAINCHEK ASSESSMENTS TRAINED DIGITALLY PER QUARTER (LHS) AND CUMULATIVE (RHS) 9,000 8,000 250,000 1,076,714 1,200,000 219,747 7,000 204,992 1,000,000 200,000 6,000 172,225 800,000 5,000 150,000 126,087 4,000 600,000 3,000
Slide 12: Growth in Global Commercial Subscriptions
GROWTH IN GLOBAL COMMERCIAL SUBSCRIPTIONS - DRIVEN BY SUCCESSFUL CONVERSION OF GOVERNMENT FUNDED BEDS CONTRACTED AND IMPLEMENTED CONTRACTED AND IMPLEMENTED NUMBER ANNUAL RECURRING REVENUE ($M) 70,000 66,032 $3.5 64,167 $3.1M $3.2M 60,000 $3.0 53,689 $2.6M 46,843 50,000 $2.5 $2.3M 39,531 $1.9 43,361
Slide 13: $4.3m ARR Expected Within 12 Months from Existing Contracts
$4.3m ARR EXPECTED WITHIN 12 MONTHS FROM EXISTING C O13N T R A C T S TRANSITION TO COMMERCIAL CONTRACTS • Government funding ends in January 2023, when (NEXT 12 MONTHS) users must convert to commercial terms 100,000 ARR ~$4.3 million $4.5 ~92,000 Beds • PainChek is achieving 80% conversion of govern
Slide 14: Integration Partners Provide Access to More Than 470,000 Aged Care Beds
INTEGRATION PARTNERS in Australia, UK, NZ and Canada provide access to more than 470,000 aged care beds PainChek works with aged care management and Integration partners support the drive to better care medication management systems covering more delivery and eliminating duplication of effort. Now t
Slide 15: Home Care Partners
HOME CARE PARTNERS In late 2021, PainChek announced our partnership Many of PainChek’s existing integration partners also with MPS Connect, a subsidiary of Sigma provide service to the large and growing home care Healthcare. market, both in Australia and globally. The PainChek Universal system is no
Slide 16: Rapid Global Market Expansion Strategy
RAPID GLOBAL MARKET EXPANSION STRATEGY Residential Home care & aged care direct to carer Leverage existing ANZ base Transition into Home care for Asia market entry through existing RAC clients and integration partners in each market Leverage existing UK base for EU market entry Build direct to Carer
Slide 17: Infant App Regulatory Cleared for Sale in Multiple Markets
INFANT APP REGULATORY CLEARED FOR SALE IN MULTIPLE MARKETS* World first facial recognition UK, CE & TGA clearance for Infant PCK infant clinical study technology to assess pre-verbal version achieved Q2 CY21 published in Lancet Digital infant post-procedural pain US market entry as a Clinical Decisi
Slide 18: How PainChek Infant Can Support HCPs & Parents
HOW PAINCHEK® INFANT CAN SUPPORT HCP’s & PARENTS BETTER MANAGE POST PROCEDURAL PAIN FOR INFANTS 1. 2. 3. 4. Infant prior to vaccination PainChek Infant available Parent is educated on If pain persists, or post surgical procedure for health care professional signs/symptoms of parent has been to docum
Slide 19: Portfolio Planning and Potential Annual Market Values
PORTFOLIO PLANNING AND POTENTIAL ANNUAL MARKET VALUES PRODUCT PLAN – MAJOR MARKETS 2022-2024 GLOBAL ANNUAL TOTAL EXISTING MARKETS 40% GLOBAL ACCESS ADDRESSABLE MARKETS Adult EU, ANZ, CANADA, SINGAPORE, UK universal B2B Residential Aged Care App Enterprise licence 2022/3 2023/4 USA CLINICAL USA FDA C
Slide 20: The Team
THE TEAM Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished global Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management Iain has over 20 year
Slide 21: The Board
THE BOARD John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Venture Philip is a highly Senior global medical Corporate finance executive 30 years execut
Slide 22: Corporate Summary
CORPORATE SUMMARY Financial information Share price (28 April 2022) A$0.041 Shares on issue 1,132.6m Market capitalisation A$46.4m Cash (31 March 2021) A$4.7m Unlisted options/performance rights 58.8m Debt Nil Top shareholders % Peters Investments Proprietary Ltd 9.98% Board & key staff 4.3% 22 |
Slide 23: Investment Highlights
INVESTMENT HIGHLIGHTS DOMINANT MARKET POSITION STRONG REVENUE GROWTH 60% market share in Australia , accelerating presence Q3 FY22 Customer revenue up 66% on prior quarter to in the UK and New Zealand, 126,000 contracted beds $304k across 1500 facilities globally ONGOING CONTRACT WINS RAPIDLY GROWIN
Slide 24: Investor Update May 2022
INVESTOR UPDATE May 2022 P HI LI P DAFF AS , P AI N CHE K LTD CEO & M D ASX :P C K 24 |